PLIANT THERAPEUTICS INC (PLRX)
US7291391057 - Common Stock
Overall PLRX gets a fundamental rating of 2 out of 10. We evaluated PLRX against 194 industry peers in the Pharmaceuticals industry. While PLRX seems to be doing ok healthwise, there are quite some concerns on its profitability. PLRX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year PLRX has reported negative net income.
In the past year PLRX has reported a negative cash flow from operations.
PLRX had negative earnings in each of the past 5 years.
PLRX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
PLRX has a Return On Assets (-45.25%) which is in line with its industry peers.
PLRX has a Return On Equity (-58.32%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.25% | ||
| ROE | -58.32% | ||
| ROIC | N/A |
ROA(3y)-36.88%
ROA(5y)-26.09%
ROE(3y)-40.76%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PLRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PLRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
PLRX has more shares outstanding than it did 1 year ago.
PLRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PLRX has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.02 indicates that PLRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
PLRX has a Altman-Z score of 2.02. This is in the better half of the industry: PLRX outperforms 68.75% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that PLRX is not too dependend on debt financing.
PLRX has a Debt to Equity ratio (0.09) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.02 |
ROIC/WACCN/A
WACC9.35%
2.3 Liquidity
PLRX has a Current Ratio of 10.26. This indicates that PLRX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 10.26, PLRX belongs to the best of the industry, outperforming 81.77% of the companies in the same industry.
PLRX has a Quick Ratio of 10.26. This indicates that PLRX is financially healthy and has no problem in meeting its short term obligations.
PLRX's Quick ratio of 10.26 is amongst the best of the industry. PLRX outperforms 81.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.26 | ||
| Quick Ratio | 10.26 |
3. Growth
3.1 Past
PLRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.71%.
Looking at the last year, PLRX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
PLRX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -66.44% yearly.
EPS 1Y (TTM)-19.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.71%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-66.44%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 6.45% on average over the next years.
The Revenue is expected to grow by 150.37% on average over the next years. This is a very strong growth
EPS Next Y-34.42%
EPS Next 2Y-22.84%
EPS Next 3Y-16.47%
EPS Next 5Y6.45%
Revenue Next Year-74.1%
Revenue Next 2Y33.27%
Revenue Next 3Y51.15%
Revenue Next 5Y150.37%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PLRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PLRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as PLRX's earnings are expected to decrease with -16.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.84%
EPS Next 3Y-16.47%
5. Dividend
5.1 Amount
No dividends for PLRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PLIANT THERAPEUTICS INC
NASDAQ:PLRX (11/25/2024, 7:03:24 PM)
After market: 12.3523 -1.11 (-8.23%)13.46
+0.48 (+3.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap819.04M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.25% | ||
| ROE | -58.32% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 10.26 | ||
| Quick Ratio | 10.26 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-19.71%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-34.42%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3Y-66.44%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y